IHG Fall/Winter Newsletter 2024 | | |
Dear IHG Community,
As we approach the end of the year, I want to extend warm wishes to each and every one of you for a happy, healthy, and safe holiday season. The Institute for Human Genetics is looking toward the future with optimism. There have been noteworthy highlights and exciting developments within our community. Let's take a moment to acknowledge and celebrate some of the positive events that have occurred this past year.
I am pleased to report on the success of our ongoing community events, particularly the Technology Seminar Series held together with the CAT and CoLabs and our IHG Seminar Series that have continued to thrive. I want to express my sincere gratitude to Laurie Weiss, PhD and Elliott Sherr, MD, PhD for their dedicated efforts in organizing our IHG Seminars. Their commitment has been instrumental in its success, allowing us to showcase the outstanding work of faculty members and present remarkable studies conducted by our trainees. These events not only contribute to the dissemination of knowledge but also foster a sense of community and collaboration within our institute. Looking ahead, we are committed to maintaining the momentum of these events and providing valuable platforms for learning, networking, and showcasing the exceptional talent within our community.
In the ever-evolving field of genetics and genomics, staying at the forefront of advancements is crucial. We had a very successful third Genotech Symposium. Our goal when establishing this annual event was to provide a consistent platform that effectively bridges the gap between industry and academia. The symposium this past September exceeded all expectations, drawing over 500 registered participants. It featured 15 speakers from diverse backgrounds, engaging panel discussions, a career panel for trainees, corporate sponsorships, and provided invaluable networking opportunities. By fostering collaboration, sharing insights, and facilitating meaningful connections we aspire to contribute significantly to the continued growth and progress of our dynamic field. The success of this year's symposium is a testament to the dedication and enthusiasm of our community. We eagerly anticipate building on this momentum, creating an even more impactful and enriching experience in the years to come. A heartfelt thank you to everyone who contributed to the success of the IHG Genotech Symposium. We look forward to many more fruitful collaborations and advancements on the horizon.
I am delighted to share the thriving success of our Genetic Counseling Master Program, a testament to the exceptional leadership of Cindy Morgan, MS. Under her guidance, the program has flourished. I want to proudly acknowledge the hard work and dedication of all students. It brings us great joy to witness the achievements of our alumni, particularly those from the inaugural cohort, who are actively contributing to the larger genetics community. These accomplishments reflect the quality of education and training provided by our program, and we are immensely proud of the impact our graduates are making in the field. A heartfelt thank you to Cindy Morgan for her outstanding leadership and to all those who contribute to the success and growth of our Genetic Counseling Master Program. We look forward to seeing continued excellence and innovation from our students and alumni in the future.
I'm very excited to inform you that our IHG experimental faculty search has led to the hiring of Dr. Chris Hsiung (details below). In addition, our computational faculty search is nearing its final stages, and we hope to hire another faculty candidate soon. I want to thank the amazing Research Committee members Drs. Sergio Baranzini, Tony Capra, David Erle, Su Guo, Ryan Hernandez, Alex Pollen, Yin Shen, Catherine Tcheandjieu, Laurie Weiss, Jimmie Ye, and Elad Ziv for all their hard work and dedication. In addition, we recently welcomed 6 new IHG members Drs. Diego Calderon, Gabriel Loeb, David Quigley, Peng He, John Liu, and Nicole DelRosso (details below). We are extremely enthusiastic about the potential contributions that these new faculty members will bring to our dynamic community.
Let us extend our heartfelt congratulations to Loïc Yengo, PhD, a statistical geneticist and Associate Professor/Director at the University of Queensland in Australia, who will be visiting our institute in 2025 from January through March as a UCSF Presidential chair and is being honored with the prestigious title of Early Career Award by the ASHG. We look forward to having Loïc as a visiting member in our institute and please feel free to reach out to him.
I would also like to take this opportunity to thank all the IHG administration staff: Stewart Begliutti, Tiffany Lai, Suzanne Mackey, Maribeth Ruperto, David Wong, Khang Nguyen, and Sharice Young. Thank you for all the amazing work you do every day for the institute! We are extremely fortunate to have you!
Thank you all for your continued dedication, hard work, and resilience. Together, we look forward to a brighter future and contributing to positive change in the world.
Looking forward to seeing everyone during our holiday party at Harmonic Brewing Thrive City on December 12th at 5PM.
Wishing you and your loved ones a peaceful holiday season.
Sincerely,
Nadav
| | Meet Our New IHG Faculty Members | | |
Dr. Diego Calderon received his BA from Wesleyan University and subsequently conducted his PhD research on the genetics underlying complex traits at Stanford University. Intrigued by massively parallel molecular biology, he then went on to become a postdoctoral fellow at the University of Washington, where he led projects involving the computational analysis of large-scale single-cell data and developed new massively parallel reporter assays to investigate gene regulation. In 2024, Diego joined UCSF as an Assistant Professor in the Department of Bioengineering and Therapeutic Sciences. The Calderon Lab broadly aims to understand all aspects of how DNA is translated into life using cutting-edge computational and experimental techniques. Our projects typically focus on using these techniques to study how DNA mutations can lead to disease or to characterize the cellular control of gene expression, but our interests encompass many topics generally related to DNA.
| |  | |
Dr. Gabriel Loeb is a physician-scientist using human genetics, genomics, organoids, and in vivo models to understand the molecular basis of kidney disease. His laboratory uses the genetics underlying both monogenic and polygenic forms of kidney disease to reveal basic disease mechanisms. Work on polygenic forms of kidney disease uses functional and single-cell genomics, machine learning, and cellular models to reveal the impact of noncoding variants on specific cell types and cell states within the kidney. Work on monogenic Polycystic Kidney Disease uses human genetics and advanced disease models to identify mechanisms of this poorly understood and challenging to treat disease.
The Loeb laboratory is dedicated to mentoring the next generation of scientists to apply genetic approaches to solving important problems in human disease.
| | | |
Dr. David Quigley's lab in UCSF's Department of Urology studies how targeted cancer therapy works and why it stops working. They particularly focus on understanding how prostate tumors develop resistance to androgen signaling inhibitors. To this end, they identify links between DNA structural variants, epigenetic changes, and patient outcomes by sequencing biopsy samples donated by cancer patients and employing integrative bioinformatics and machine learning methods. Recent epigenomic studies from my group and our collaborators have identified transcriptional drivers of treatment-resistant prostate cancer. They have also performed the first large studies of the chromatin conformation of metastatic prostate tumor using ATAC-seq and HiC. Their goal is to reconstruct how the tumor responds to therapy pressure by interrogating the tumor’s genome, epigenome, and transcriptome. With this information, they can understand the biology of lethal cancer, develop new biomarkers to select which patients will respond to therapy, and understand how therapy resistance develops.
| | | |
Dr. Peng He investigates how genes are orchestrated to control cell state changes during development and disease. His laboratory creates high-resolution roadmaps of cell types and states through innovative single-cell and spatial -omic computational analyses. By tracking gene expression dynamics in tissues and precisely perturbed organoids, his team aims to uncover how gene regulatory networks give rise to complex tissue structures and functions.
| | | |
Dr. John Liu's lab, the Liu Lab at UCSF, is an interdisciplinary basic and translational research group dedicated to understanding the biology and advancing new treatments for malignant brain tumors. They are interested in the mechanisms of tumorigenesis and treatment resistance. They develop and apply cutting-edge functional genomic approaches collaboratively to achieve this mission. Research areas in the lab include:
1) Discovery of novel cancer targets using functional genomics.
2) Role of DNA damage response in radiation treatment resistance.
3) Epigenetic engineering as novel precision therapeutics.
| | | |
Dr. Nicole DelRosso received her PhD from the Department of Biophysics at Stanford University in 2024. She worked in the labs of Dr. Lacramioara Bintu and Dr. Polly Fordyce where she discovered hundreds of transcriptional effector domains in human cells and provided the first quantitative map of their disordered interactions with cofactors using a novel microfluidic platform she developed to measure protein-protein binding affinities in high-throughput. The DelRosso Lab at UCSF builds high-throughput techniques to systematically identify molecular interactions that regulate transcription in human cells. They aim to not only understand how disordered proteins recognize their partners to regulate gene expression strength and timing, but also eventually program these interactions to accomplish new functions in human cells.
| | |
|
Chris Hsiung, MD, PhD
Dr. Chris Hsiung enjoys pondering and tinkering with the flow of genetic information in biological systems for fundamental understanding and therapeutic applications. Current research themes in the Hsiung Lab include:
1) Understanding and engineering cell type-specific transcription, cell differentiation and epigenetic memory.
2) Developing efficient approaches to exploring numerous combinatorial genetic perturbations.
3) Applying functional genomics approaches to understand and engineer emergent properties of tissues, including tissue responses to injury and immune recognition of cancer.
| | | | |
Sharice Young oversees HR operations as the HR Liaison of the Institute for Human Genetics at the University of California, San Francisco.
She began her career at UCSF in 2006 as an Office Assistant at the Institute for Health and Aging as well as the Department of Social and Behavioral Sciences, quickly advancing to the role of HR Specialist in 2007. Over the years, she has gained a vast array of experience as a Benefits Analyst in the Controller’s Office and Payroll Analyst in the HR Service Center's Transaction Unit before joining the Institute for Human Genetics in 2019.
Sharice is currently the primary point of contact for personnel matters, working closely with faculty and administration to facilitate HR actions and ensure compliance with departmental policies. Her responsibilities encompass managing onboarding and offboarding processes, overseeing the People Connect ticketing system, and providing guidance on academic personnel policies, all while upholding confidentiality and fostering diversity and inclusion.
Outside of work, Sharice enjoys gardening and quality time with her children!
| |
Loïc Yengo, PhD - 2024 ASHG Early Career Award
The ASHG Early Career Award recognizes early career independent investigators whose work has had a significant impact on the field of human genetics. Dr. Loïc Yengo is a statistical geneticist and currently Associate Professor/Director at the University of Queensland in Australia, who has already made groundbreaking contributions to population genetics and the study of complex diseases. We are also excited that he will be a UCSF Presidential Chair visiting us for the winter quarter, 2025 from January through March. Dr. Yengo is recognized for his innovative ideas and impactful research including notable contributions to the discovery of genes responsible for inter-individual variation in complex traits such as human height and risk of common disease. Learn more about Dr. Yengo’s work.
Nadav Ahituv, PhD - 2024 ASHG Scientific Achievement Award
The ASHG Scientific Achievement Award recognizes genetics and genomics researchers who have made significant scientific contributions during the past decade. Dr. Ahituv is a professor in the Department of Bioengineering and Therapeutic Sciences and the director of the Institute for Human Genetics at the University of California, San Francisco. Dr. Ahituv is recognized for his extensive collaborative research that has led to scientific advances in genomic technologies and gene therapy that have the potential to revolutionize human genetics and the treatment of genetic and genomic disorders. Learn more about Dr. Ahituv’s work.
| | | |
David Wong (Financial Analyst of the Institute for Human Genetics at the University of California, San Francisco) is recognized for the 2024 School of Medicine STAR Achievement Award! The Staff Appreciation and Recognition Program ("STAR Program") is a cash recognition program to recognize and reward excellence in university service, significant achievements and contributions, and/or outstanding individual and team performance.
| | | | Institute for Human Genetics Exploratory Grant | |
|
Drs. Sparks, Cromer, and Mackenzie's proposal entitled “Developing innovative in utero therapy for non-immune hydrops fetalis and RASopathies” has been selected for the Institute for Human Genetics Exploratory Grant Initiative for funding in the amount of $50,000!
Strengths:
In this proposal, 2 clinician-scientists (Sparks and MacKenzie) and 1 basic scientist (Cromer) are working together to develop prenatal therapies for fetuses with nonimmune hydrops fetalis (NIHF) and severe, early-onset single gene disorders. If successful, the approach can be applied broadly and be used to treat single gene disorders in utero. The 3 aims of the proposal are feasible within the funding period and will lay the foundation for a biobank of fetuses with NIHF, develop somatic gene editing strategies for patients with RASopathies, and correlate specific RASopathy disease and genotype with severity of in utero disease and postnatal outcomes. The work will be able to demonstrate the feasibility of treating RASopathy patient by somatic gene editing. If successful, it will take prenatal treatment of an important group of NIHF patients to a new level and high likelihood of NIH granting support.
Weaknesses:
Somatic gene editing takes time (especially when one must screen multiple edited cell lines to make sure that no deleterious off-target effects are present) and fetal development progresses rapidly, it may be challenging to get the fetus treated in time before major developmental defects appear. However, this is a practical problem that is not within the scope of the proposal.
| | | |
Four scientists and clinicians at UC San Francisco have been honored in 2024 with election to the American Academy of Arts & Sciences (AAA&S), one of the nation’s oldest and most distinguished societies. | From left to right: W. Thomas Boyce, MD; Kathleen Giacomini, PhD; Geeta Narlikar, PhD; and Neil Powe, MD, MPH, MBA. | | | |
Three UC San Francisco scientists have received 2024 Pew awards to fund their research in neuroscience and cancer. They include a cognitive scientist, Vijay Mohan K Namboodiri, PhD, who is challenging the reigning theory of learning; Justin Eyquem, PhD, a bioengineer who aims to build cancer-fighting cell therapies from within a person’s body; and Jovanka Gencel-Augusto, PhD, a postdoctoral scholar from Peru who is studying cancer genetics. | | | |
UCSF Prostate Cancer Program is the recipient of the National Cancer Institute’s (NCI) Specialized Programs of Research Excellence (SPORE) grant for prostate cancer. The program will receive about $7 million to develop new approaches to the prevention, early detection, diagnosis and treatment of prostate cancer. The prostate cancer SPORE will be co-led by Eric J. Small, MD, FASCO, a medical oncologist who is a UCSF professor of medicine and urology, co-leader of the UCSF Prostate Cancer Program and deputy director and chief scientific officer of the UCSF Helen Diller Family Comprehensive Cancer Center (HDFCCC), and Felix Feng, MD, a radiation oncologist who is a professor of radiation oncology, urology and medicine at UCSF and co-leader of the UCSF Prostate Cancer Program. | | | |
|
Mercedes Paredes, MD, PhD, a researcher at the Eli and Edythe Broad Center of Regeneration Medicine and Stem Cell Research, together with Nadav Ahituv, PhD, from the Institute of Human Genetics; Kevin Bender, PhD, from the Center for Integrative Neuroscience; Young Shin Kim, MD, PhD, from the UCSF STAR Center for Neurodevelopmental Disorders; and Roy Ben-Shalom, PhD, from UC Davis MIND, has been awarded a $6.25 million grant from the California Institute for Regenerative Medicine (CIRM) to pioneer a novel approach for treating CNS-associated microdeletion syndromes, with a focus on 22q deletion syndromes.
Microdeletion syndromes, which cause severe neuropsychiatric symptoms and cognitive impairments, currently have few treatment options. Dr. Paredes' research aims to restore gene function by upregulating multiple genes—an innovative strategy designed by Dr. Ahituv's team, that could lead to a breakthrough in genetic disorder treatment. If successful, the project could reshape therapeutic approaches for neuropsychiatric conditions while advancing the broader understanding of brain function.
With a high-risk, high-reward approach, the study will also incorporate clinical outreach and patient advocacy to ensure research aligns with patient needs. The method’s potential impact extends beyond microdeletion syndromes, offering hope for broader applications in genetic and neuropsychiatric therapies. It also highlights the importance of patient-driven science to frame cell therapy development.
| | | | |
Our 2024 Institute for Human Genetics Genotech Symposium was a huge success with captivating talks that focused on basic science and translational work across selected topics in gene therapy, AI, and genomic technologies.
With over 500 registrants, there were many fruitful interactions and collaborations with talks by industry leaders/faculty, panel discussions, and social events.
Special thanks to our sponsors Agilent, Hitachi High-Tech, Nabsys, Novogene, Complete Genomics, S2 Genomics, Illumina, Scale Biosciences, 10x Genomics, Integrated DNA Technologies, and Curio Bioscience for helping make this event possible!
We thank you all for your participation and look forward to seeing you next year.
| | Spatial and single cell diversity | | |
The initial promise of single cell omics was that it could revolutionize our understanding of intra-sample cellular diversity. From a Precision Medicine perspective, however, we want to understand inter-sample diversity, i.e. differences between patients. Using examples from colorectal cancer (CRC), chronic myeloid leukaemia (CML) and type 1 diabetes (T1D), I will show how single cell RNA-seq (scRNA-seq) can help us achieve both objectives.
We can also investigate the diversity of healthy humans by the same methods. To understand how ethnicity and genetic ancestry influenced human physiology we profiled 1,265,624 peripheral blood mononuclear cells from 619 individuals from 7 population groups in 5 Asian countries. We uncovered profound molecular and cellular differences between these 7 groups, including cell populations and genes with diagnostic and prognostic relevance. Our results suggest that ethnicity-specific or ancestry-specific diagnostic and therapeutic strategies may be needed to fulfil the promise of Precision Medicine across the globe.
With the availability of robust commercial solutions for subcellular-resolution spatial RNA profiling, spatial technologies are taking over the space hitherto occupied by single cell omics. Data analysis is now the major bottleneck. We developed BANKSY, a spatial clustering algorithm that uses a cell’s physical neighbourhood as a guide to its own identity. BANKSY is an order of magnitude more scalable than competing methods. Independent benchmarking studies have shown that it is also the most accurate. We also developed MEDOC, a spatial omics algorithm that optimally clusters cells by morphology. We used these two methods in conjunction with large-scale MERFISH and Xenium spatial RNA profiling to identify markers of tumour budding in CRC and nuclear morphology in chronic myelomonocytic leukaemia (CMML).
| | | Characterizing functional genomic diversity in Island Southeast Asia: lessons and challenges | | Genetic Variation: From Quantification to Risk Prediction | | Analyzing, sharing, and translating high-throughput functional assay data | | Spatiotemporal modeling of molecular holograms | |
Seminar will be rescheduled:
The role of silencer variants in human diseases
| | Technology Seminar Series | | |
The UCSF Institute for Human Genetics, Center for Advanced Technology, and CoLabs co-host the lunch and learn technology seminar series. These seminars are free and open to all. They occur every second Tuesday of the month and bring researchers to hear about the latest technologies and applications.
Lunch and Learn Tech Seminar Schedule:
9/10/24: Oxford Nanopore Technologies
10/8/24: Thermo Fisher Scientific
11/12/24: Complete Genomics
12/10/24: 10x Genomics
1/14/25: ScaleBio
2/11/25: Illumina, BioModal, and N6tec
3/11/25: Olink, part of Thermo Fisher Scientific
4/8/25: Takara Bio
5/13/25: Oxford Nanopore Technologies
6/10/25: Mawi DNA
7/8/25: Mission Bio
8/12/25: VWR/Avantor
9/9/25: Complete Genomics
10/14/25: Promega
11/11/25: PacBio
12/9/25: EpiCypher
1/13/26: Nabsys
2/10/26: Vector Builder
3/10/26: Olink, part of Thermo Fisher Scientific
4/14/26: BioChain Institute
| | September 2024: Oxford Nanopore Technologies | |
|
Speakers:
Satu Strandman (Account Executive, Oxford Nanopore Technologies)
Alan Silverman (Regional Sequencing Specialist, Oxford Nanopore Technologies)
Nelson Garcia (Field Applications Specialist, Oxford Nanopore Technologies)
For questions or advice on experimental design, contact:
satu.strandman@nanoporetech.com
| | | |
|
“One thing for those who are Lord of the Rings fans, you know, the one ring who rules them all. We have the one pore that rules them all, at least for DNA. Regardless of device and flow cell, the pore is the same.”
- Alan Silverman,
Oxford Nanopore Technologies
Regional Sequencing Specialist
| | | | | October 2024: Thermo Fisher Scientific | |
|
Speakers:
Mark Lund (Technical Sales Specialist, Thermo Fisher Scientific)
David Covarrubias (Technical Sales Specialist, Thermo Fisher Scientific)
Anna Lim (Technical Sales Specialist, Thermo Fisher Scientific)
For questions or advice on experimental design, contact:
desola.ilupeju@thermofisher.com
| | | | November 2024: Complete Genomics | |
Speakers:
Parker Heissenbuttel (Account Executive, Complete Genomics)
Andrew Kebbel (Technical Sales Specialist, Complete Genomics)
Hui Shen (Division of Biomedical Informatics & Genomics Professor and Associate Director, Tulane University)
For questions or advice on experimental design, contact:
pheissenbuttel@completegenomics.com
| | | | December 2024: 10x Genomics | | February 2025: Illumina, BioModal, and N6tec | |
Speakers:
Greg Kronmal (Sr Executive Sales Specialist, Illumina)
Jennifer Stone (Global Head of Business Development and Customer Solutions, biomodal)
Chris Streck (Head of Commercial, n6 Tec)
For questions or advice on experimental design, contact:
gkronmal@illumina.com
Jennifer.stone@biomodal.com
chris@n6tec.com
| | | |
The UCSF Genetic Counseling Program recently traveled to New Orleans for the NSGC Annual Education Conference, and it was an incredible experience! Along with soaking up cutting-edge content, we had the pleasure of hosting a lively reunion event that brought together our students, alumni, and a wonderful mix of program supporters. It was a fantastic opportunity to reconnect, celebrate our community, and share stories of success and growth. | | | | |
Ready to take the next step in your academic journey? Watch our interactive webinar where you’ll get an inside look at our graduate program and learn about the admissions process. The live Q&A session connected directly with our leadership team. | | | |
|
Are you passionate about healthcare and interested in a rewarding career in Genetic Counseling? This is your chance to explore an exciting profession and connect with over 50 Master’s Degree programs from across the country — including the UCSF Genetic Counseling Program!
Why Attend?
- Learn about a growing healthcare field that blends science and patient care.
- Explore over 50 top-tier Genetic Counseling programs.
- Meet representatives from UCSF! Learn about our program, speak with current students, and discover what makes UCSF a leading choice for your genetic counseling education.
Don’t miss out on this incredible opportunity to connect with UCSF and many other programs while jumpstarting your career in genetic counseling!
Registration is free and you can join from anywhere!
| | | |
|
The Genetics Student Interest Group has organized an event on 11/14 at Parnassus Campus (with snacks). Please join us!
Location:
UCSF Medical Sciences Building, Suite HSW-303
513 Parnassus Avenue
San Francisco, CA 94143
| | | |
Come in your favorite winter attire to our UCSF IHG Holiday Party! Please RSVP by taking this survey ASAP. Looking forward to celebrating together! | | | |
|
I am the CEO and co-founder of Alida Biosciences and am thrilled to share our latest commercial platform to enhance multiomic research. EpiPlex™ is a novel platform to detect, identify, and quantitate RNA modifications together with gene expression data, and includes bioinformatic analysis. The current assay targets m6A and inosine with high accuracy. Additional benefits include low RNA input (as low as 250 ng total RNA), a streamlined & quick assay (7 hours), and free of charge access to an end-to-end analysis pipeline.
To give our local research community the first look at this transformative innovation, I will be in town to host an onsite meeting:
Date: December 18, 2024
Time: 10 am PST
Location: UCSF Genentech Hall, Room S261*
Purpose: Introduction to the technology, live data demonstration, Q&A with technology founder
Whether you're actively exploring solutions or simply curious about the future of epitranscriptomics, we would love to have you join us.
Please RSVP by December 16, 2024 by submitting this RSVP Form. Space may be limited, so we encourage early registration.
Best regards,
Dr. Gudrun Stengel
CEO & Co-Founder, AlidaBio
gstengel@alidabio.com
*Seminar location details:
UCSF Genentech Hall, Room S261
600 16th Street, San Francisco, CA 94158
Attention: all non-UCSF guests please sign in at the security desk and mention you are going to seminar room S261.
Alida Biosciences, 11535 Sorrento Valley Rd, Suite 407, San Diego, California 92121
| | | |
|
Dear colleagues,
We just wanted to send a reminder about our fifth annual NIH Diversity Supplement Matchmaking Event, which will be on January 30, 2025 from 9am-1pm. We already have over 40 applicants signed up, which is quite a bit more than we’ve had at this point in past years, so we’re anticipating that there will be a lot of applicants for you to meet!
If you are interested in attending the Matchmaking Event, please register here by December 4th.
The event will be virtual (by zoom), which allows us to extend invitations to trainees from around the country. The event will provide you with an opportunity to have short, 15-minute interviews with trainees at the postbaccalaureate stage who are interested in pursuing a career in research and qualify for funding through the NIH Diversity Supplement mechanism. This NIH grant mechanism typically provides salary support for the trainee to work in your lab as a Junior Specialist for 1-2 years. You must have an eligible NIH grant to apply for the funds and the applications are submitted directly to the NIH through the institute that is funding your grant. However, you do not need to have an eligible grant to participate in the event—all faculty who are looking to hire a research technician are welcome to attend.
If you make a match with a trainee, we have several resources to help you write for the supplement, including a collection of successful Diversity Supplement applications from UCSF PIs and additional resources. In addition, trainees who come to UCSF through this mechanism will have the opportunity to participate in PROPEL, which is a UCSF postbaccalaureate program that provides historically underrepresented trainees with research experience, scientific and careering training to become competitive and successful applicants to top-tier research-based PhD programs.
If you have any questions about the Matchmaking event and applying for Diversity Supplements, see here and here for FAQs or attend our faculty information session on Wednesday, Nov 22nd, 11:00-12:00pm. Register for the info session here.
I hope to see you there!
--Todd
| | | | |
We invite you to be part of our journey! Help us grow our Institute and support our efforts to further human genetics research and education and the application of this important work to human disease and patient care. Donations of all sizes expand our impact across the field of human genetics and, in particular, to our faculty and student researchers. Please consider making a tax deductible donation. We are most grateful!
Donate Online
After clicking on the button below, make a gift.
| | Thank you - We appreciate your support | | | | |
